Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations
Canadian Agency for Drugs and Technologies in Health
Record ID 32011001017
English
Authors' recommendations:
Although evidence-based recommendations support the use of stimulants as first line therapy when treating children with ADHD, the recommendation to use long acting formulations over short acting is based on expert opinion. Considerations include patient preference, convenience, compliance, reducing stigma, and the potential for drug diversion.
Details
Project Status:
Completed
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Attention Deficit Disorder with Hyperactivity
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.